{"filing":{"accession_number":"0001193805-26-001071","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-06","primary_document":"e665684_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_8k-immunic.htm"},"events":[{"id":26855,"run_id":24424,"accession_number":"0001193805-26-001071","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Immunic reported financial results for Q2 2026 ended June 30, 2026, and provided a corporate update via press release.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28132,"accession_number":"0001193805-26-001071","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Immunic's financial results for Q2 2026 ended June 30, 2026, via a press release furnished as Exhibit 99.1. The filing explicitly states the company \"reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.\" This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and operational progress toward pivotal Phase 3 clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26856,"run_id":24424,"accession_number":"0001193805-26-001071","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Elena Ridloff was appointed to the Board of Directors effective August 6, 2026, bringing 20+ years of biopharmaceutical leadership experience in finance, capital markets, and corporate development to strengthen the board's expertise as the company approaches pivotal Phase 3 readout. Dr. Daniel Vitt resigned from the board and his employment was terminated pursuant to a separation agreement.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28133,"accession_number":"0001193805-26-001071","item_number":"5.02","item_title":"Departure of Directors or Principal Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The section discloses the appointment of Elena Ridloff as a director on August 6, 2026, with detailed background on her qualifications and experience in finance and life sciences. While the section also discloses Dr. Daniel Vitt's resignation from the board and termination of employment with a separation agreement, the primary focus and most salient event is the board appointment of Ridloff, a qualified executive with significant CFO and capital markets experience, at a critical juncture for the company's Phase 3 trials and potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28134,"accession_number":"0001193805-26-001071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the appointment of Elena Ridloff to the Board of Directors, effective August 6, 2026. The press release emphasizes her 20+ years of biopharmaceutical leadership experience in finance, capital markets, and corporate development, and explicitly states the appointment \"strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise\" as the company approaches pivotal Phase 3 readout and potential regulatory filings. This is a material executive/board appointment that would affect a reasonable investor's assessment of the company's governance and leadership capacity during a critical clinical and commercial phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28132,"accession_number":"0001193805-26-001071","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Immunic's financial results for Q2 2026 ended June 30, 2026, via a press release furnished as Exhibit 99.1. The filing explicitly states the company \"reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.\" This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and operational progress toward pivotal Phase 3 clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-08-11"},{"id":28133,"accession_number":"0001193805-26-001071","item_number":"5.02","item_title":"Departure of Directors or Principal Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The section discloses the appointment of Elena Ridloff as a director on August 6, 2026, with detailed background on her qualifications and experience in finance and life sciences. While the section also discloses Dr. Daniel Vitt's resignation from the board and termination of employment with a separation agreement, the primary focus and most salient event is the board appointment of Ridloff, a qualified executive with significant CFO and capital markets experience, at a critical juncture for the company's Phase 3 trials and potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-08-11"},{"id":28134,"accession_number":"0001193805-26-001071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the appointment of Elena Ridloff to the Board of Directors, effective August 6, 2026. The press release emphasizes her 20+ years of biopharmaceutical leadership experience in finance, capital markets, and corporate development, and explicitly states the appointment \"strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise\" as the company approaches pivotal Phase 3 readout and potential regulatory filings. This is a material executive/board appointment that would affect a reasonable investor's assessment of the company's governance and leadership capacity during a critical clinical and commercial phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:17.215487+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-08-11"}]}